SOURCE: TalkPoint

TalkPoint

July 09, 2010 11:18 ET

FDAAdvisoryCommittee.com to Webcast Joint Committee Review of Blood Glucose Drug AVANDIA

Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Committee Will Be Streamed Live and Archived for Six Months

NEW YORK, NY--(Marketwire - July 9, 2010) -  FDAAdvisoryCommittee.com (FDAAC.com), a provider of live video webcasts of Food and Drug Administration (FDA) Advisory Committee meetings, today announced that it will webcast the two-day joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Committee as they discuss the cardiovascular safety of AVANDIA®, a blood glucose control drug for adults with type 2 diabetes. The meetings are scheduled to occur on July 13, 2010 from 8:00 a.m. ET to 6:00 p.m., and on July 14, 2010 from 8:00 a.m. to 5:00 p.m. ET.

This is the second time that GlaxoSmithKline's AVANDIA (rosiglitazone maleate) has come under review since the FDA approved it in 1999. In 2007, the FDA reviewed the safety of AVANDIA after meta-analysis studies found that the drug led to increased risk of heart attack, stroke, heart failure and death. At the time, the FDA voted to keep AVANDIA on the market. The debate over AVANDIA's safety has grown more recently, as three new studies show conflicting findings that both support and refute those previous findings.

Audience members, including biotech equity analysts, pharmaceutical employees, and journalists, will be able to watch from anywhere in the world as the Committees present data on AVANDIA derived from multiple trials and studies. The FDA will also present its meta-analysis of several trials of Takeda Pharmaceuticals' ACTOS (pioglitazone hydrochloride), an alternative treatment for type 2 diabetes, and compare the safety of the two drugs. 

FDAAC.com is committed to delivering the highest quality of video and experience. By utilizing h.264 encoding in conjunction with Flash Media, FDAAC.com's webcasts deliver a near instantaneous stream. These high-quality streams can be accessed from anywhere around the globe and are archived for six months after the live event for unlimited review.

FDAAC.com's webcasts are powered by TalkPoint, a provider of Web-based audio and video Webcasting solutions and services. With over a decade of experience, TalkPoint has developed the most robust, scalable, interactive webcasting platform in the industry. TalkPoint's easy-to-use applications incorporate audio, video, slides, and other interactive elements to deliver high-impact webcasts cost-effectively.

To join the webcasts on July 13 and 14, at 8 a.m. ET register at
http://fdaac.com

About FDAAdvisoryCommittee.com
FDAAC.com provides live video webcasts of FDA Advisory Committee meetings captured on location. These meetings cover an array of topics related to medicinal health including OTC, prescription and treatment devices. Very often meetings will result in rulings on clinical trials, final approval and bans of medications and treatment options. TalkPoint is the exclusive webcast provider for FDAAdvisoryCommittee.com.

For more information on FDAAC.com, go to www.fdaac.com.

Contact Information

  • Media Contacts:
    Richard Taber
    FDAAdvisoryCommittee.com
    Tel: (800) 627-8171
    Email Contact

    Jeff Horan
    LVA Communications
    Tel: (860) 739-5598
    Email: Email Contact